HORMAD1 and neoplasm: By identifying bimodal and tumour cell specific somatic expression of the meiotic protein HORMAD1 as a potential patient selection biomarker our study contributes to a growing body of evidence that TLS dependency is a tractable therapeutic target in cancer.